Studies published in the Lancet and the New England Journal of Medicine this week provide the basis for this article in the Wall Street Journal, which reports that "patients with a particular gene variant seem to respond less effectively to the anticlotting agent Plavix than those with the normal version of the gene." Researchers wonder whether higher doses of Plavix would make a difference for people with the variant, or whether the drug will simply be ineffective for them, noting that more studies are needed.
Â